CN104093402A - Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用 - Google Patents

Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用 Download PDF

Info

Publication number
CN104093402A
CN104093402A CN201380006947.7A CN201380006947A CN104093402A CN 104093402 A CN104093402 A CN 104093402A CN 201380006947 A CN201380006947 A CN 201380006947A CN 104093402 A CN104093402 A CN 104093402A
Authority
CN
China
Prior art keywords
unsubstituted
compound
replace
pharmaceutically
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380006947.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·约文
M·斯奎雷斯
C·雷迪克
张勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104093402A publication Critical patent/CN104093402A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380006947.7A 2012-01-31 2013-01-30 Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用 Pending CN104093402A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593047P 2012-01-31 2012-01-31
US61/593,047 2012-01-31
PCT/US2013/023781 WO2013116293A1 (en) 2012-01-31 2013-01-30 Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN104093402A true CN104093402A (zh) 2014-10-08

Family

ID=47679114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380006947.7A Pending CN104093402A (zh) 2012-01-31 2013-01-30 Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用

Country Status (12)

Country Link
US (1) US20140378422A1 (enExample)
EP (1) EP2809312A1 (enExample)
JP (1) JP2015505562A (enExample)
KR (1) KR20140117457A (enExample)
CN (1) CN104093402A (enExample)
AU (1) AU2013215251A1 (enExample)
BR (1) BR112014017985A8 (enExample)
CA (1) CA2861377A1 (enExample)
IN (1) IN2014DN05869A (enExample)
MX (1) MX2014009303A (enExample)
RU (1) RU2014135436A (enExample)
WO (1) WO2013116293A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111787922A (zh) * 2018-01-10 2020-10-16 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
CN112912078A (zh) * 2018-09-13 2021-06-04 恒翼生物医药科技(上海)有限公司 用于治疗雌激素受体阳性乳腺癌的组合疗法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2940576A1 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
WO2016152907A1 (ja) 2015-03-25 2016-09-29 国立研究開発法人国立がん研究センター 胆管癌治療剤
CN108495628B (zh) * 2015-12-09 2022-01-11 伊利诺伊大学评议会 苯并噻吩基选择性雌激素受体下调剂
CN108367000A (zh) 2015-12-17 2018-08-03 卫材R&D管理有限公司 用于乳腺癌的治疗剂
KR102793563B1 (ko) 2016-03-04 2025-04-11 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
WO2018148576A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
EP4353222A1 (en) 2018-03-19 2024-04-17 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
WO2019189241A1 (ja) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
WO2020110974A1 (ja) * 2018-11-26 2020-06-04 大鵬薬品工業株式会社 線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法
CA3185174A1 (en) * 2020-07-31 2022-02-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
CN120022281A (zh) * 2021-03-03 2025-05-23 正大天晴药业集团股份有限公司 Cdk4/6抑制剂的联用药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081445A2 (en) * 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics Inc. Treatment of metastasized tumors
CN101222850A (zh) * 2005-05-13 2008-07-16 诺瓦提斯公司 治疗对药物有抗性的癌症的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (enExample) 1962-09-13
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
ATE309996T1 (de) 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
ITTV20030095A1 (it) 2003-07-14 2005-01-15 Asolo Spa Calzatura con sottopiede composito.
JP4890255B2 (ja) 2003-11-07 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
AU2006249847B2 (en) 2005-05-23 2012-12-20 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
NZ567550A (en) 2005-11-29 2011-08-26 Novartis Ag Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one
US20080206194A1 (en) * 2007-02-16 2008-08-28 Glazer Robert I Method for the treatment of breast cancer
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081445A2 (en) * 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics Inc. Treatment of metastasized tumors
CN101222850A (zh) * 2005-05-13 2008-07-16 诺瓦提斯公司 治疗对药物有抗性的癌症的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DANIEL E. LOPES DEMENEZES,ET AL: "CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia", 《CLIN CANCER RES》 *
JULIEN H. DEY, ET AL: "Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis", 《CANCER RESEARCH》 *
NICHOLAS TURNER, ET AL.: "FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer", 《CANCER RESEARCH》 *
VICTORIA KNIGHTS, ET AL.: "De-regulated FGF receptors as therapeutic targets in cancer", 《PHARMACOLOGY & THERAPEUTICS》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111787922A (zh) * 2018-01-10 2020-10-16 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
US11833119B2 (en) 2018-01-10 2023-12-05 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
CN112912078A (zh) * 2018-09-13 2021-06-04 恒翼生物医药科技(上海)有限公司 用于治疗雌激素受体阳性乳腺癌的组合疗法

Also Published As

Publication number Publication date
AU2013215251A1 (en) 2014-08-14
US20140378422A1 (en) 2014-12-25
RU2014135436A (ru) 2016-03-27
MX2014009303A (es) 2014-10-14
KR20140117457A (ko) 2014-10-07
EP2809312A1 (en) 2014-12-10
IN2014DN05869A (enExample) 2015-05-22
WO2013116293A1 (en) 2013-08-08
BR112014017985A2 (enExample) 2017-06-20
CA2861377A1 (en) 2013-08-08
BR112014017985A8 (pt) 2017-07-11
JP2015505562A (ja) 2015-02-23

Similar Documents

Publication Publication Date Title
CN104093402A (zh) Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用
AU2021282467B2 (en) AR+ breast cancer treatment methods
US9421208B2 (en) Methods for the treatment of solid tumors
JP6926066B2 (ja) 癌を治療するための方法
US20130345217A1 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
JP2013525291A (ja) 肝がんの治療に使用するための有機化合物
JP2015536986A (ja) 併用療法
US20140275089A1 (en) 2-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative Diseases
EP1885187B1 (en) Methods for treating drug resistant cancer
US8962679B2 (en) Daidzein analogs as treatment for cancer
CN104661681B (zh) 包含磷脂酰肌醇3-激酶抑制剂和芳香酶抑制剂的药物组合
TW201420102A (zh) 組合療法
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
BR112018076001B1 (pt) Uso de rad140 (composto iii) para tratamento de câncer de mama ar+/ er+"
CA3072389A1 (en) Selective beta2-adrenergic receptor antagonist for treating von hippel-lindau
HK1110477B (en) Methods for treating drug resistant cancer
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use
NZ617243A (en) Combinations of akt and mek inhibitor compounds, and methods of use
KR20150064857A (ko) 혈관 신생작용 관련 질환 치료를 위한 HIF-1α 저해 화합물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141008